Last reviewed 2026-04-22 · How we verify

SCT800 and Daratumumab

SCT800 is a bispecific antibody that simultaneously engages CD19 on B cells and CD3 on T cells to redirect T-cell killing of CD19+ malignant cells, while daratumumab is a monoclonal antibody targeting CD38 on plasma cells to induce their apoptosis.

SCT800 is a bispecific antibody that simultaneously engages CD19 on B cells and CD3 on T cells to redirect T-cell killing of CD19+ malignant cells, while daratumumab is a monoclonal antibody targeting CD38 on plasma cells to induce their apoptosis. Used for Multiple myeloma (in combination), B-cell non-Hodgkin lymphoma (SCT800 component).

At a glance

Mechanism of action

SCT800 functions as a T-cell engager (BiTE) that bridges cytotoxic T lymphocytes to CD19-expressing B-cell malignancies, enhancing T-cell activation and tumor cell lysis. Daratumumab binds CD38, a surface antigen highly expressed on multiple myeloma cells and other hematologic malignancies, triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. The combination leverages complementary mechanisms to target plasma cell dyscrasias and B-cell malignancies.

Approved indications

• Multiple myeloma (in combination)
• B-cell non-Hodgkin lymphoma (SCT800 component)

Common side effects

• Cytokine release syndrome
• Infusion-related reactions
• Neutropenia
• Anemia
• Thrombocytopenia
• Infection

Key clinical trials

• ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.